CHYM enters September in a peculiar position — up nearly 38% in a month but surrendering 4.4% in a single session, with insiders cashing out and analysts scrambling to catch up on price targets they only just raised.
The analyst story is almost uniformly constructive, yet the targets keep moving. Morgan Stanley maintained its Overweight and lifted its target to $39. Wolfe Research raised to $38. Wells Fargo moved to $39. The freshest action came this week, with Scotiabank initiating at Sector Outperform with a $40 target — the highest initiation on the name in recent weeks. The consensus mean sits at $34.80, just above Tuesday's close of $31.66. Most of the post-earnings target hikes were reactive rather than forward-looking; the stock printed a 25% single-day move on August 5 earnings, and analysts largely chased the level rather than led it. The bull case rests on ARPAM growing 6% to $245, platform revenue compounding at a 90% quarterly pace, and an EBITDA margin that expanded nearly 900 basis points to 5.3%. The bear case is equally clear: an untested credit model in a difficult macro environment, potential pricing pressure from card networks, and member acquisition costs that could widen again if growth slows.
Positioning does not yet reflect the kind of skepticism the bears are arguing. Short interest runs at 5.7% of free float — meaningful enough to watch, but it has actually been declining. It fell roughly 8.3% on the week and nearly 10% over the past month, dropping from a peak near 23 million shares in early August to just under 19.6 million. The borrowing market is loose — availability is running at over 4,600%, meaning there are vastly more shares available to lend than are currently borrowed. Cost to borrow, though up 41% on the week, remains low in absolute terms at 0.53%. Nothing in the lending market suggests a meaningful build of short conviction. Options traders lean modestly bullish: the put/call ratio is at 0.56, roughly one standard deviation below its 20-day mean of 0.61, a mild but clear tilt toward calls. The August 21 peak of 0.72 — which represented the most defensive options posture of the past year — has retreated quickly.
The more interesting signal this week is the insider tape. DST Global, the largest disclosed holder at roughly 10.4% of shares, sold approximately $35 million of stock on August 26 across several tranches — none of it under a 10b5-1 plan. That is a discretionary sale, not a scheduled distribution. Meanwhile, CEO Christopher Britt sold just over $3 million on August 28, though that was under a pre-arranged plan and carries less informational weight. The 90-day net insider figure tells the broader story: net sales of over $203 million across the last three months. Co-founders Britt and Ryan King both appear in the top holders list with recent reductions — Britt trimmed by 562,160 shares and King by 379,187 shares. These are not distress signals on their own — post-IPO selling by VC backers and founders is standard. But DST's unplanned block sale, while holding over 39 million shares, is worth watching as an indication of the appetite to reduce exposure at current prices.
Earnings history at this stock is dramatic. The two most recent prints produced single-day moves of roughly 25% and 12%, with five-day follow-through of 27% and 24% respectively. The next event is not until November 5, so the immediate catalyst window is closed. What sits between now and then is the broader question of whether the 38% one-month rally is pricing in the next beat, or whether it simply reflects the market catching up to what the Q2 report already showed. With peers under pressure — AFRM down 10% on the week, PYPL off 16%, and PAYS down 12% — CHYM's relative resilience is notable, but the gap between a $31.66 close and a Street mean target of $34.80 is not as wide as it looks after a 4.4% single-session drop.
The combination of one-sided analyst upgrades, easing short interest, loose borrow conditions, and a slightly call-skewed options market paints a picture of cautious optimism — the DST discretionary sale is the single thread that pulls against the consensus grain, and how aggressively that holder continues to trim from its 10.4% stake is the clearest thing to monitor into year-end.
See the live data behind this article on ORTEX.
Open CHYM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
